MultiVir, Inc., a clinical-stage gene therapy firm headquartered in Houston, TX, focuses on the development of cutting-edge treatment solutions for various cancer types. Its novel product candidates identify and target the fundamental molecular defects of cancer using gene therapy and oncolytic viral technologies. These treatments deploy genetically engineered adenoviruses, herpes simplex viruses, and vaccinia viruses to introduce therapeutic genes into tumors. Established on November 5, 2009, the company's operations primarily entail developing innovative cancer treatments.

Tags

Neoplasms

Oncolytic virus

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Oncolytic virus	1

Top 5 Target	Count

ADP(Adenovirus death protein)	1

Drugs associated with Multivir, Inc.

Oncolytic adenovirus gene therapy(Multivir, Inc.)

Target

ADP

Mechanism

ADP stimulants [+1]

Active Org.

Originator Org.

Active Indication

Inactive Indication

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date-

Interleukin 24 gene therapy(Multivir, Inc.)

Target

IL-24

Mechanism

IL-24 stimulants [+1]

Active Org.-

Originator Org.

Multivir, Inc.

Active Indication-

Inactive Indication

Head and Neck Neoplasms [+1]

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date-

HSV-Rb-p450

Target-

Mechanism

Gene transference [+1]

Active Org.-

Originator Org.

Multivir, Inc.

Active Indication-

Inactive Indication

Colorectal Cancer

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Multivir, Inc.

NCT02842125 / TerminatedPhase 1/2

Phase 1/2 Evaluation of Adenoviral p53 (Ad-p53) in Combination With Capecitabine (Xeloda) or Anti-PD-1 in Patients With Unresectable Liver Metastases of Colorectal Carcinoma(CRC) and Other Solid Tumors, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) and Primary Hepatic Cancers With Known Disease Progression on Standard Therapy

This is a Phase 1/2 study of the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine or pembrolizumab in patients with unresectable, refractory liver metastases of colorectal carcinoma (CRC) and other solid tumors, including primary hepatocellular carcinoma (HCC). A third arm will study the intra-tumoral injection of Ad-p53 combined with nivolumab infusions in recurrent head and neck squamous cell cancer (HNSCC). This safety study has a standard 3+3 design for arms A and B; .HNSCC will be placed in a single dosing cohort. The Maximum Tolerated Dose (MTD) will be determined as well for intra-arterial infusions, and the entire study will determine the general efficacy using RECIST 1.1 and Immune-Related Response Criteria. Safety will be followed using the CTCAE listings for adverse events.

Start Date20 Nov 2018

Sponsor / Collaborator

Multivir, Inc.

NCT03544723 / Unknown statusPhase 2

A Phase 2, Multi-Center, Open Label Study to Evaluate Adenoviral p53 (Ad-p53) in Combination With Immune Checkpoint Inhibitor Therapy in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Tumors Approved for Anti-PD-1 or Anti-PD-L1 Therapy

This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers. Comparison will be made to historical data. General safety and efficacy using RECIST 1.1 and Immune-Related Response Criteria as well as ECOG performance will be utilized.

Start Date01 Oct 2018

Sponsor / Collaborator

Multivir, Inc.

NCT03406715 / TerminatedPhase 2IIT

Combination Immunotherapy With Ipilimumab and Nivolumab Plus a Dendritic Cell Based p53 Vaccine (Ad.p53-DC) in Patients With Relapsed Small Cell Lung Cancer (SCLC)

The purpose of this study is to find out what effects (good and bad) immunotherapy treatment using the p53 vaccine (Ad.p53-DC) in combination with Nivolumab and Ipilimumab has on small cell lung cancer. Immunotherapy is a cancer therapy that uses the body's immune system to fight cancer cells.
This study can be divided into three different phases: initial Induction Immunotherapy, Maintenance Immunotherapy and Retreatment.

Start Date15 Mar 2018

Sponsor / Collaborator

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+2]

100 Clinical Results associated with Multivir, Inc.

0 Patents (Medical) associated with Multivir, Inc.

Literatures (Medical) associated with Multivir, Inc.

01 Jun 2022·Cancer Gene TherapyQ2 · MEDICINE

Tumor suppressor immune gene therapy to reverse immunotherapy resistance

Q2 · MEDICINE

Article

Author: Chada, Sunil ; Talbott, Max ; Menander, Kerstin B ; Ahn, Hyo Min ; Jung, Bo-Kyeong ; Wiederhold, Dora ; Sellman, Beatha ; Sobol, Robert E ; Yun, Chae-Ok ; Nemunaitis, John J

AbstractBackgroundWhile immune checkpoint inhibitors are becoming a standard of care for multiple types of cancer, the majority of patients do not respond to this form of immunotherapy. New approaches are required to overcome resistance to immunotherapies.MethodsWe investigated the effects of adenoviral p53 (Ad-p53) gene therapy in combination with immune checkpoint inhibitors and selective IL2 or IL15 CD122/132 agonists in the aggressive B16F10 tumor model resistant to immunotherapies. To assess potential mechanisms of action, pre- and post- Ad-p53 treatment biopsies were evaluated for changes in gene-expression profiles by Nanostring IO 360 assays.ResultsThe substantial synergy of “triplet” Ad-p53 + CD122/132 + anti-PD-1 therapy resulted in potential curative effects associated with the complete tumor remissions of both the primary and contralateral tumors. Interestingly, contralateral tumors, which were not injected with Ad-p53 showed robust abscopal effects resulting in statistically significant decreases in tumor size and increased survival (p < 0.001). None of the monotherapies or doublet treatments induced the complete tumor regressions. Ad-p53 treatment increased interferon, CD8+ T cell, immuno-proteosome antigen presentation, and tumor inflammation gene signatures. Ad-p53 treatment also decreased immune-suppressive TGF-beta, beta-catenin, macrophage, and endothelium gene signatures, which may contribute to enhanced immune checkpoint inhibitor (CPI) efficacy. Unexpectedly, a number of previously unidentified, strongly p53 downregulated genes associated with stromal pathways and IL10 expression identified novel anticancer therapeutic applications.ConclusionsThese results imply the ability of Ad-p53 to induce efficacious local and systemic antitumor immune responses with the potential to reverse resistance to immune checkpoint inhibitor therapy when combined with CD122/132 agonists and immune checkpoint blockade. Our findings further imply that Ad-p53 has multiple complementary immune mechanisms of action, which support future clinical evaluation of triplet Ad-p53, CD122/132 agonist, and immune checkpoint inhibitor combination treatment.

10 Feb 2018·Journal of Clinical Oncology

Reversing immune checkpoint inhibitor resistance with adenoviral IL-24 and p53 tumor suppressor immune gene therapy.

Author: Yun, Chae-Ok ; Chada, Sunil ; Menander, Kerstin ; Sobol, Robert E. ; Wiederhold, Dora B ; Oh, Eonju ; Ahn, Hyomin

64 Background: Immune checkpoint inhibitors represent an important advance in cancer therapeutics. However, most cancer patients either do not respond or become resistant to this therapy. Methods: We evaluated the ability of tumor suppressors p53 and IL-24, delivered via adenoviral vectors, to reverse immune checkpoint inhibitor resistance and induce abscopal therapeutic effects in the highly immune therapy resistant murine B16F10 melanoma tumor model. To mimic clinical conditions of immune checkpoint inhibitor resistance, animals with established tumors were treated with anti-PD-1 before intra-tumoral delivery of adenoviral vectors encoding tumor suppressors p53 (Ad-p53) or IL-24 (Ad-IL24). Results: Anti-PD-1 had minimal or no therapeutic efficacy when compared to PBS controls. However, there was a reversal of anti-PD-1 resistance in animals treated with Ad-p53, or Ad-IL24, in combination with anti-PD-1. Evaluation of primary tumor growth using ANOVA confirmed synergistic effects of the combination treatments over either agent used as monotherapy (p = 0.0001 for p53, p = 0.002 for IL-24). We also observed statistically significant decreases in contralateral abscopal tumor growth in animals whose primary tumors were treated with either Ad- p53 or Ad-IL24 (p = 0.046, and p = 0.0021, respectively) or in combination with anti-PD-1 (p = 0.02 p53, and p < 0.0001 for IL-24) as compared to animals treated with anti-PD-1 alone. With respect to survival, combined tumor suppressor + anti-PD-1 therapy resulted in a statistically significant increase in survival compared to: a) tumor suppressor therapy alone (p = 0.01 for either Ad-p53 and or IL-24) and b) anti-PD-1 therapy alone (p < 0.001 for p53, and p = x for IL-24). Conclusions: Overall, these results indicate that IL-24 and p53 tumor suppressor immune gene therapy can reverse immune checkpoint inhibitor resistance in primary tumors, and induce abscopal effects inferring the activation of systemic anti-tumor immune responses that reverse resistance to immune checkpoint inhibitor therapy.

20 May 2017·Journal of Clinical Oncology

Effect of adenoviral p53 (Ad-p53) tumor suppressor immune gene therapy on checkpoint inhibitor resistance and abscopal therapeutic efficacy.

Author: Yun, Chae-Ok ; Wiederhold, Dora Bocangel ; Oh, Eonju ; Menander, Kerstin B. ; Subbiah, Vivek ; Sobol, Robert E. ; Chada, Sunil ; Ahn, Hyomin ; Murthy, Ravi

e14610 Background: Immune checkpoint inhibitors represent an important advance in cancer therapeutics. However, most cancer patients do not respond or become resistant to this form of immune therapy. Methods: We evaluated the ability of Ad-p53 to reverse immune checkpoint inhibitor resistance and induce abscopal effects in the immune therapy resistant murine B16F10 melanoma tumor model. To mimic clinical conditions of checkpoint inhibitor resistance, animals with established tumors were treated with anti-PD-1 before initiating Ad-p53 intra-tumoral therapy. Results: Anti-PD-1 had minimal therapeutic efficacy compared to control treatment. A statistical analysis of variance (ANOVA) comparison of tumor volumes revealed that the combined effect of Ad-p53 and anti-PD-1 treatment was synergistic and superior to either therapy alone (p = 0.0001). Surprisingly, there was a statistically significant abscopal effect with decreased growth of contralateral tumors not injected with Ad -p53. The Ad- p53 alone (p = 0.046) and Ad- p53 + anti-PD-1 (p = 0.0243) treatment groups both demonstrated a statistically significant decreased abscopal tumor growth compared to treatment with anti-PD-1 alone. Combined Ad- p53 and anti-PD-1 therapy demonstrated a statistically significant increase in survival compared to Ad- p53 therapy alone (p = 0.0167) and anti-PD-1 therapy alone (p < 0.001) by the log rank test. We have initiated a Phase 1 clinical trial of Ad-p53 intra-hepatic arterial therapy in combination with capecitabine for patients with solid tumor liver metastases. In the first cohort of patients at a dose of 2 x 1012viral particles, treatment has been well tolerated with transient fever, chills and rigors. In one patient, decreased SUV uptake on PET scans of distant lymph node metastases suggested possible abscopal effects. Conclusions: These results suggest that Ad-p53 tumor suppressor immune gene therapy may reverse immune checkpoint inhibitor resistance and induce abscopal effects supporting the planned clinical evaluation of combined Ad-p53 and anti-PD-1 therapy in patients resistant to immune checkpoint inhibitor therapy. Clinical trial information: NCT02842125.

News (Medical) associated with Multivir, Inc.

15 Feb 2021

·www.globenewswire.com

Global Gene Therapy Market Outlook to 2030 - by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration and Key Geographical Regions

Dublin, Feb. 15, 2021 (GLOBE NEWSWIRE) -- The "Gene Therapy Market by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering. Over time, several gene therapies have been developed for the treatment of both simple and complex genetic disorders. In fact, there are 10 approved gene therapies (recent examples include Zolgensma, ZyntegloT and Collategene) to date, and more than a thousand product candidates being evaluated in clinical trials, worldwide. Considering the current pace of research and product development activity in this field, experts believe that the number of clinical research initiatives involving gene therapies are likely to grow by 17% annually. In this context, the USFDA released a notification, mentioning that it now expects to receive twice as many gene therapy applications each year, starting 2020. Despite the ongoing pandemic, it is worth highlighting that gene therapy companies raised approximately USD 5.5 billion in capital investments, in 2020 alone. This is indicative of the promising therapeutic potential of this emerging class of pharmacological interventions, which has led investors to bet heavily on the success of different gene therapy candidates in the long term. Several technology platforms are currently available for discovery and development of various types of gene therapies. In fact, advances in bioanalytical methods and genome editing and manipulation technologies, have enabled the development of novel therapy development tools/platforms. In fact, technology licensing is a lucrative source of income for stakeholders in this industry, particularly for those with proprietary gene editing platforms. Given the growing demand for interventions that focus on the amelioration of the underlying (genetic) causes of diseases, it is expected that the gene therapy pipeline will continue to steadily expand. Moreover, promising results from ongoing clinical research initiatives are likely to bring in more investments to support therapy product development initiatives in this domain. Therefore, we are led to believe that the global gene therapy market is poised to witness significant growth in the foreseen future. The report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies, immunotherapies and gene editing therapies. The study also features an elaborate discussion on the future potential of this evolving market. Key Questions Answered Who are the leading industry players engaged in the development of gene therapies? How many gene therapy candidates are present in the current development pipeline? Which key disease indications are targeted by such products? Which types of vectors are most commonly used for effective delivery of gene therapies? What are the key regulatory requirements for gene therapy approval, across various geographies? Which commercialization strategies are most commonly adopted by gene therapy developers, across different stages of development? What are the different pricing models and reimbursement strategies currently being adopted for gene therapies? What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies? Who are the key CMOs/CDMOs engaged in supplying viral/plasmid vectors for gene therapy development? What are the key value drivers of the merger and acquisition activity in the gene therapy industry? Who are the key stakeholders that have actively made investments in the gene therapy domain? Which are the most active trial sites related to this domain? How is the current and future market opportunity likely to be distributed across key market segments? Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. GENE DELIVERY VECTORS 5. REGULATORY LANDSCAPE AND REIMBURSEMENT SCENARIO 6. MARKET OVERVIEW 7. COMPETITIVE LANDSCAPE 8. MARKETED GENE THERAPIES 9. KEY COMMERCIALIZATION STRATEGIES 10. LATE STAGE GENE THERAPIES 11. EMERGING TECHNOLOGIES 12. KEY THERAPEUTICS AREAS 13. PATENT ANALYSIS 14. MERGERS AND ACQUISITIONS 15. FUNDING AND INVESTMENT ANALYSIS 16. CLINICAL TRIAL ANALYSIS 17. COST PRICE ANALYSIS 18. BIG PHARMA PLAYERS: ANALYSIS OF GENE THERAPY RELATED INITIATIVES 19. DEMAND ANALYSIS 20. MARKET FORECAST AND OPPORTUNITY ANALYSIS 21. VECTOR MANUFACTURING 22. CASE STUDY: GENE THERAPY SUPPLY CHAIN 23. CONCLUSION A Selection of Companies Mentioned Include: 4BIO Capital 4D Molecular Therapeutics AavantiBio aaVective AAVogen AbbVie Allergan AlphaVax Altheia Science Amgen Amplo Angionetics ApolloBio Arthrogen Astellas Pharma AstraZeneca Atlas Venture Atsena Therapeutics AVROBIO Baillie Gifford Baldota Group Bayer Biogen BridgeBio Bristol-Myers Squibb Calimmune Cardiogen Sciences Casdin Capital Codexis CSL Behring Editas Medicine Fundacion Sanfilippo B Google Ventures Gradalis Green Cross Holdings GSK Handl Therapeutics Hovione Scientia Intrexon Invus IVERIC bio Janssen Pharmaceuticals Johnson & Johnson Development Juda Capital K2 Venture Capital Lacerta Therapeutics MeiraGTx Merck MERITZ Securities Mitsubishi Tanabe Pharma MultiVir Myonexus Therapeutics Navega Therapeutics NeoMed Nerveda Omega Funds Omnes Capital OrbiMed ORI Capital Otonomy Oxford BioMedica Oxular REGENXBIO Renova Therapeutics Roche Sanofi StrideBio Surveyor Capital Syncona Synpromics T. Rowe Price Takeda Pharmaceutical Targovax Temasek Tenaya Therapeutics TheraBiologics Theravectys Tocagen WuXi AppTec XyloCor Therapeutics Ysios Capital Ziopharm Oncology For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Gene TherapyAcquisition

100 Deals associated with Multivir, Inc.

100 Translational Medicine associated with Multivir, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 20 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Oncolytic adenovirus gene therapy(Multivir, Inc.) ( ADP )	Neoplasms More	Phase 1
HSV-Rb-p450	Colorectal Cancer More	Pending
HSV Rb-p450 gene therapy(Multivir, Inc.) ( CYPs )	Colorectal Cancer More	Pending
Interleukin 24 gene therapy(Multivir, Inc.) ( IL-24 )	Head and Neck Neoplasms More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis